ALS (CPBLF) Loans Receivable : $0 Mil (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is ALS Loans Receivable?

ALS's Loans Receivable for the quarter that ended in Sep. 2024 was $0 Mil.

ALS Loans Receivable Historical Data

The historical data trend for ALS's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALS Loans Receivable Chart

ALS Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Loans Receivable

Get a 7-Day Free Trial

ALS Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

ALS Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

ALS Loans Receivable Related Terms

Thank you for viewing the detailed overview of ALS's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

ALS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » ALS Ltd (OTCPK:CPBLF) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

ALQ:Australia

Address

25 King Street, Level 9B, Bowen Hills, Brisbane, QLD, AUS, 4006

Website

https://www.alsglobal.com

Founded in the 1880s and listing on the ASX in 1952, ALS operates three divisions: commodities, life sciences, and industrial. ALS commodities traditionally generated the majority of underlying earnings, providing geochemistry, metallurgy, inspection and mine site services for the global mining industry. Expansion into environmental, pharmaceutical and food testing areas and commodity price weakness have lessened earnings exposure to commodities.